Surgical meshes play a significant role in the treatment of various medical conditions, such as hernias, pelvic floor issues, guided bone regeneration, and wound healing. To date, commercial surgical meshes are typically made of non-absorbable synthetic polymers, notably polypropylene and polytetrafluoroethylene, which are associated with postoperative complications, such as infections. Biological meshes, based on native tissues, have been employed to overcome such complications, though mechanical strength has been a main disadvantage. The right balance in mechanical and biological performances has been achieved by the advent of bioresorbable meshes. Despite improvements, recurrence of clinical complications associated with surgical meshes raises significant concerns regarding the technical adequacy of current materials and designs, pointing to a crucial need for further development. To this end, current research focuses on the design of meshes capable of biomimicking native tissue and facilitating the healing process without post-operative complications. Researchers are actively investigating advanced bioresorbable materials, both synthetic and natural biopolymers, while also exploring the performance of therapeutic agents, surface modification methods and advanced manufacturing technologies such as 4D printing. This review seeks to evaluate emerging biomaterials and technologies for enhancing the performance and clinical applicability of the next-generation of surgical meshes. STATEMENT OF SIGNIFICANCE: In the ever-transforming landscape of regenerative medicine, the embracement of engineered bioabsorbable surgical meshes stands as a key borderline in addressing persistent challenges and complications associated with existing treatments. The urgency to move beyond conventional non-absorbable meshes, fraught with post-surgery complications, emphasises the necessity of using advanced biomaterials for engineered tissue regeneration. This review critically examines the growing field of absorbable surgical meshes, considering their potential to transform clinical practice. By strategically marrying mechanical strength with bioresorbable characteristics, these innovative meshes hold the promise of mitigating complications and improving patient outcomes across diverse medical applications. As we navigate the complexities of current medicine, this exploration of engineered absorbable meshes emerges as a light of hope, offering an overall perspective on biomaterials, technologies, and strategies adopted to redefine the future of surgical meshes.

Tissue engineering combines a scaffold, cells and regulatory signals, reproducing a biomimetic extracellular matrix capable of supporting cell attachment and proliferation. We examined the role of an electrospun scaffold made of a biocompatible polymer during the myogenesis of skeletal muscle (SKM) as an alternative approach to tissue regeneration. The engineered nanostructure was obtained by electrospinning poly(L-lactide-co-ε-caprolactone) (PLCL) in the form of a 3D porous nanofibrous scaffold further coated with collagen. C2C12 were cultured on the PLCL scaffold, and cell morphology and differentiation pathways were thoroughly investigated. The functionalized PLCL scaffold recreated the SKM nanostructure and performed its biological functions, guiding myoblast morphogenesis and promoting cell differentiation until tissue formation. The scaffold enabled cell–cell interactions through the development of cellular adhesions that were fundamental during myoblast fusion and myotube formation. Expression of myogenic regulatory markers and muscle-specific proteins at different stages of myogenesis suggested that the PLCL scaffold enhanced myoblast differentiation within a shorter time frame. The functionalized PLCL scaffold impacts myoblast bioactivity and acts as a stimulus for cell commitment, surpassing traditional 2D cell culture techniques. We developed a screening model for tissue development and a device for tissue restoration.

In‐vitro models are fundamental for studying muscular cell contractility and for wide‐screening of therapeutic candidates targeting skeletal muscle diseases, owing to their scalability, reproducibility, and circumvention of ethical concerns. However, in‐vitro assays permitting reliable electrical stimulation of cell contractile activity still require technological development. Here, a novel approach to electrically stimulate differentiated muscular cell contractility is reported exploiting the ionic conductivity and mechanical flexibility of 3D nanofibrous scaffolds. The electrospun poly(L‐lactide‐co‐caprolactone) scaffold allowed for C2C12 murine myoblasts horizontal elongation and myotubes formation. Scaffold porosity enables high ionic conductivity and strong electric field generation, orthogonally oriented to the scaffold surface. Electrically induced cell contractility is determined with atomic force microscopy (AFM) enabling real‐time monitoring of scaffold vibrations in liquid environment. Differentiated cell actuation is found to be linearly correlated to current amplitude and number of current stimuli. Integrating the 3D nanofibrous scaffolds with real‐time AFM monitoring provides highly accurate in‐vitro assays for biomedical research. The induction of electric fields orthogonal to the scaffold surface allows for accurately mimicking the excitation‐contraction coupling mechanism observed in native skeletal muscle tissue. This work paves the way for the quantitative study of muscular cell dynamic behavior and physiology, further evaluating therapy effectiveness for muscular pathologies.

Inflammation mechanisms play a critical role in muscle homeostasis, and in Muscular Dystrophies (MDs), the myofiber damage triggers chronic inflammation which significantly controls the disease progression. Immunomodulatory strategies able to target inflammatory pathways and mitigate the immune-mediated damage in MDs may provide new therapeutic options. Owing to its capacity of influencing the immune response and enhancing tissue repair, stem cells’ secretome has been proposed as an adjunct or standalone treatment for MDs. In this review study, we discuss the challenging points related to the inflammation condition characterizing MD pathology and provide a concise summary of the literature supporting the potential of perinatal stem cells in targeting and modulating the MD inflammation.